Matschurat Susanne, Knies Ulrike E, Person Veronika, Fink Ludger, Stoelcker Benjamin, Ebenebe Chinedu, Behrensdorf Heike A, Schaper Jutta, Clauss Matthias
Department of Molecular Cell Biology, Max-Planck-Institute for Physiological and Clinical Research, Bad Nauheim, Germany.
Am J Pathol. 2003 Jan;162(1):93-103. doi: 10.1016/S0002-9440(10)63801-1.
Endothelial-monocyte-activating polypeptide II (EMAP II) is a proinflammatory cytokine and a chemoattractant for monocytes and granulocytes. We have previously shown that EMAP II mRNA is strongly expressed at sites of apoptosis in the mouse embryo and that the mature protein is cleaved from its cellular precursor (proEMAP II/p43) by caspase activation to become released from cells. Here we demonstrate in vivo that EMAP II mRNA expression is strongly increased in tumor necrosis factor alpha (TNF)-treated murine meth A fibrosarcomas and in B16 melanomas, especially in close proximity to areas of tissue necrosis. Furthermore, by means of confocal microscopy, high level expression of proEMAP II/p43 protein correlated predominantly with hypoxic but also with apoptotic cells. In vitro, EMAP II mRNA levels were not increased by hypoxia. However, high amounts of mature EMAP II protein were detected in the supernatants of hypoxic tumor cells. Unlike in apoptotic cells, neither a broad-range caspase inhibitor nor an inhibitor specific for the internal cleavage site was able to inhibit processing of proEMAP II/p43 to the mature EMAP II protein. In conclusion, these data suggest that hypoxia and apoptosis provide two alternative mechanisms of EMAP II generation by tumor cells.
内皮单核细胞激活多肽II(EMAP II)是一种促炎细胞因子,也是单核细胞和粒细胞的趋化因子。我们之前已经表明,EMAP II mRNA在小鼠胚胎的凋亡部位强烈表达,并且成熟蛋白通过半胱天冬酶激活从其细胞前体(proEMAP II/p43)上切割下来,从而从细胞中释放出来。在此我们在体内证明,在肿瘤坏死因子α(TNF)处理的小鼠甲基胆蒽A纤维肉瘤和B16黑色素瘤中,EMAP II mRNA表达强烈增加,尤其是在靠近组织坏死区域。此外,通过共聚焦显微镜观察,proEMAP II/p43蛋白的高水平表达主要与缺氧细胞相关,但也与凋亡细胞相关。在体外,缺氧不会增加EMAP II mRNA水平。然而,在缺氧肿瘤细胞的上清液中检测到大量成熟的EMAP II蛋白。与凋亡细胞不同,广谱半胱天冬酶抑制剂和针对内部切割位点的特异性抑制剂均不能抑制proEMAP II/p43加工成成熟的EMAP II蛋白。总之,这些数据表明缺氧和凋亡为肿瘤细胞产生EMAP II提供了两种替代机制。